Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs

• Main Authors: Daniela Drago, Betsy Foss-Campbell, Keith Wonnacott, David Barrett, Adora Ndu
• Format: Article
• Language: English
• Published: Elsevier 2021-06-01
• Series: Molecular Therapy: Methods & Clinical Development
• Subjects: Food and Drug Administration; European Medicines Agency; Gene Therapy; Advanced Therapies; Regenerative Medicine; Regulation
• Online Access: http://www.sciencedirect.com/science/article/pii/S2329050121000668

The rapid expansion of the gene therapy pipeline in recent years offers significant potential to treat diseases with great unmet medical need. However, the unique nature of these therapies poses challenges to regulating them within traditional frameworks, even when developing in a single country. Various factors exacerbate the issues in commercializing products across regions, including the lack of established regulatory frameworks for developing gene therapy products in many jurisdictions. While some countries have established separate regulatory frameworks for advanced therapies/regenerative medicine products, differences exist between them. Recommended solutions to overcome these hurdles include fostering convergence among countries with separate regulatory frameworks for these products and utilizing reliance and recognition for countries without such frameworks. Additionally, regulators who choose to establish new dedicated frameworks for regulating gene therapies should consider the inclusion of key elements such as expedited regulatory pathways that offer early engagement with regulators, innovative clinical trial design, and adequate post-market confirmatory studies. Increasing the alignment of regulatory pathways across countries will be crucial to facilitating the development of, and access to, gene therapies on a global scale.